Search Results - pandemic

3 Results Sort By:
Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Zhijian Duan, Jesse Buffington
Keywords(s): : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron
Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...
Published: 7/29/2024   |   Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan
Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing
Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays
This invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. CDC researchers have developed a rapid, accurate, real-time RT-PCR assay that has several advantages over culture and serological tests, which require 5 to 14 days for completion; this assay can also be easily implemented in kit form....
Published: 10/28/2024   |   Inventor(s): Stephen Lindstrom, Kai-Hui Wu, LaShondra Berman, Bo Shu
Keywords(s): assay, ASSAYS, CDC Docket Import, CDC Docket Import CDC Prosecuting, CIRCULATING, DA4BXX, DA4XXX, DAXXXX, Detection, diagnostic, Diagnostic assay, diagnostic in vitro, discrimination, DXXXXX, Flu, H3, H3N2, H3v, Including, INFLUENZA, ivd, Pandemic, REAL-TIME, RT-PCR, Seasonal, VARIANT, virus, Viruses, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX
Category(s): Collaboration Sought > Licensing, Application > Occupational Safety and Health, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Research Materials, Application > Diagnostics